{"created":"2023-07-27T06:56:10.118179+00:00","id":52850,"links":{},"metadata":{"_buckets":{"deposit":"0d069c18-2352-4ebe-89f0-f9a39fc523d7"},"_deposit":{"created_by":18,"id":"52850","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"52850"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00052850","sets":["2812:2813:2817"]},"author_link":["2668"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-06-14","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2015-04-01 – 2017-03-31","bibliographic_titles":[{"bibliographic_title":"平成28(2016)年度 科学研究費補助金 若手研究(B) 研究成果報告書"},{"bibliographic_title":"2016 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"乳癌のサブタイプのうちホルモン受容体陽性のルミナルタイプの患者に対してはホルモン療法が効果的でありHER2陽性タイプは抗HER2療法が生存予後を改善することが知られている。しかしこれらの受容体を発現しないトリプルネガティブタイプ乳癌(TNBC)に対しては、治療法は化学療法のみと限られており、他のサブタイプに比べて悪性度が高く予後不良である。そのため、TNBCの早期診断と治療標的分子の同定が必要とされている。本研究ではおよそ2000名の乳癌患者の遺伝子発現データから294名のTNBC患者を抽出し解析を行った結果、TNBC患者ではKLK3高発現群は予後不良であることが明らかになった。","subitem_description_type":"Abstract"},{"subitem_description":"Breast cancer is the most common cancer among women. Developments in the treatment of some types of breast cancer have increased the overall survival of patients. Tamoxifen that is an antagonist of the estrogen receptor and trastuzumab that is a monoclonal antibody that acts in the HER2 receptor have improved the survival outcome of luminal and Her2 breast cancer subtypes, respectively. However, triple negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, usually presents a poor outcome. Because of poor prognosis and a more aggressive phenotype, there is an urgent clinical need to identify novel therapeutic targets for TNBCs. To identify new therapeutic targets in TNBC, we analyzed gene expression data of a cohort composed of 294 patients diagnosed with TNBC and identified Kallikrein-related-peptidase 3 (KLK3) as a biomarker for TNBC.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:15K18426, 研究期間(年度):2015-04-01 – 2017-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：「乳癌におけるKLK3(PSA)の腫瘍マーカーとしての検討および治療標的の探索」研究成果報告書　課題番号15K18426\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-15K18426/15K18426seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学がん進展制御研究所","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00059143","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/search/?kw=70597921"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/search/?kw=70597921","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-15K18426/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-15K18426/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-15K18426/15K18426seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-15K18426/15K18426seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-10-12"}],"displaytype":"detail","filename":"CA-PR-NAKADA-A-kaken 2017-4p.pdf","filesize":[{"value":"267.8 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"CA-PR-NAKADA-A-kaken 2017-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/52850/files/CA-PR-NAKADA-A-kaken 2017-4p.pdf"},"version_id":"a2076295-b675-464e-a7d6-f6937f04b888"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"乳癌におけるKLK3(PSA)の腫瘍マーカーとしての検討および治療標的の探索","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"乳癌におけるKLK3(PSA)の腫瘍マーカーとしての検討および治療標的の探索"},{"subitem_title":"Evaluation of KLK3 as a biomarker for breast cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2817"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-10-12"},"publish_date":"2020-10-12","publish_status":"0","recid":"52850","relation_version_is_last":true,"title":["乳癌におけるKLK3(PSA)の腫瘍マーカーとしての検討および治療標的の探索"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T11:20:22.330708+00:00"}